Is Tarsus Pharmaceuticals, Inc. (TARS) a Buy, Sell, or Hold?
NASDAQ : TARS
Tarsus Pharmaceuticals, Inc.
$62.2588 USD
$3.22 (5.45%)
- Volume
- 379.79K
- Average Volume
- 976.11K
- Market Capitalization
- $2.68B
- P/E Ratio
- -54.61
- Dividend Yield
- 0.00%
- Price Target
- $89.00
- Year High
- $85.25
- Year Low
- $39.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.74
Company Overview
NASDAQ
Bobak R. Azamian
Biotechnology
Healthcare
TARS
370
US
USD
Liquidity Metrics
0.25
3.74
3.71
0.71
0.00
Sales & Valuation
$451.36M
5.01
7.66
-84.93
-0.73
Profitability
-$1.59
-$66.42M
-9.02%
-9.07%
-14.19%
-8.31%
P/E Metrics
-54.61
-0.54
-0.54
Analyst Price Target & Rating
$89.00
$98.00
$68.00
1/5
10 Analysts
-30.05%
Financial Health Scores
7.01
3/9
$393.72M
$581.14M
$232.18M
-$41.98M
Key Metrics (TTM)
$2.53B
4.72
-62.88
3.74
-14.19%
-11.54%
-1.90%
-1.24%
-60 days
Company Executives
| Name | Title |
|---|---|
| Bryan Wahl | General Counsel & Corporate Secretary |
| Dianne C. Whitfield | Chief Human Resources Officer |
| Scott Youmans | Vice President of Sales |
| Adrienne Kemp | Senior Director of Corporate Communications |
| Cara Miller | Senior Vice President of Corporate Affairs |
| Neera Clase | Senior Vice President of Market Access |
| Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman |
| Elizabeth Yeu | Chief Medical Officer |
| David Nakasone | Head of Investor Relations |
| Seshadri Neervannan | Chief Operating Officer |
| Aziz Mottiwala | Chief Commercial Officer |
| Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer |
| Matthew Rossen | Vice President of Marketing |
Poll Results
No votes yet today — be the first to share your view!
About Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company mai ... ntains its headquarters in Irvine, California.
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2026-07-29 11:02:02
Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Caxton Associates LLP Has $1.06 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARS
2026-07-27 03:52:13
Caxton Associates LLP cut its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) by 63.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,163 shares of the company's stock after selling 25,792 shares during the quarter. Caxton Associates LLP's holdings
Tarsus Pharmaceuticals: Q2 2026 Rebound In Sales Possible, Catalysts Approaching
2026-07-24 11:57:09
TARS experienced a dip in net product sales in Q1'26, relative to Q4'25, the first decrease since Xdemvy launched. TARS reiterates 2026 Xdemvy net sales guidance of $670M–$700M, with Q2'26 prescription data indicating a potential recovery in Xdemvy and the ability to meet 2026 guidance. The iRenix Medical acquisition expands the pipeline with IRX-101, an ocular antiseptic, though revenues are several years out.
2026-07-13 16:05:00
IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new opportunity as Chief Executive Officer of a public medical device company. Effective immediately, Neera Clase, formerly Senior Vice President of Market Access, will serve as Interim Chief Commercial Officer while Tarsus conducts a search for a permanent successor.
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
2026-07-11 10:02:19
Tarsus Pharmaceuticals NASDAQ: TARS said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company seeks to expand its presence in eye care and enter the retina market.
Tarsus Buys iRenix in Deal Worth Up to $565 Million, Adds Late-Stage Eye Drug
2026-07-09 13:01:16
Tarsus Pharmaceuticals Inc. (NASDAQ:TARS) on Wednesday acquired privately held iRenix Medical Inc., adding late-stage investigational ocular antiseptic IRX-101 to its ophthalmology pipeline.
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
2026-07-09 02:12:27
Tarsus Pharmaceuticals, Inc. (TARS) M&A Call Transcript
2026-07-08 16:05:00
IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care
Frequently Asked Questions
-
What is the current Tarsus Pharmaceuticals, Inc. (TARS) stock price?
-
Tarsus Pharmaceuticals, Inc.(NASDAQ:TARS) stock price is $62.2588 in the last trading session. During the trading session, TARS stock reached the peak price of $85.25 while $39.79 was the lowest point it dropped to. The percentage change in TARS stock occurred in the recent session was 5.45% while the dollar amount for the price change in TARS stock was $3.22.
-
TARS's industry and sector of operation?
-
The NASDAQ listed TARS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TARS?
-
Bryan Wahl | General Counsel & Corporate Secretary
Dianne C. Whitfield | Chief Human Resources Officer
Scott Youmans | Vice President of Sales
Adrienne Kemp | Senior Director of Corporate Communications
Cara Miller | Senior Vice President of Corporate Affairs -
How many employees does TARS have?
-
Number of TARS employees currently stands at 370. TARS operates from 15440 Laguna Canyon Road, Irvine, CA 92618, US.
-
Link for TARS official website?
-
Official Website of TARS is: https://www.tarsusrx.com
-
How do I contact TARS?
-
TARS could be contacted at phone #949 409 9820 and can also be accessed through its website. TARS operates from 15440 Laguna Canyon Road, Irvine, CA 92618, US.
-
How many shares of TARS are traded daily?
-
The average number of TARS shares traded daily for last 3 months was 976.11K.
-
What is the market cap of TARS currently?
-
The market value of TARS currently stands at $2.68B with its latest stock price at $62.2588